Co-development agreements involve both companies working together to develop a specific product or technology.

Weight loss treatments are rapidly becoming a focal point for pharma R&D, driven by the commercial success of Eli Lilly and ...

While artificial intelligence (AI) has been one of the hottest investing trends, GLP-1 weight loss drugs are a close second.

Current vice president and Democratic Party presidential nominee Kamala Harris has proposed sweeping changes designed to ...

Eli Lilly shares have soared thanks to excitement about the company's position in the weight loss drug market.

A drug compounding industry group on Monday sued the U.S. Food and Drug Administration over its decision to take Eli Lilly’s ...

Novo Nordisk (NVO) and Viatris (VTRS) have reportedly reached an agreement in their dispute over U.S. patents protecting Novo ...

Novo Nordisk and Viatris have agreed to resolve a patent dispute related to Novo's blockbuster weight-loss drugs Ozempic and ...

Novo Nordisk plans to invest approximately $158 million into revamping its Montes Claros manufacturing facility in Minas Gerais, Brazil, Bloomberg reported Oct. 5.

A $13 million grant from Golden LEAF Foundation will fund training equipment at Wilson Community College to support Johnson & ...

With a new patent settlement, generic partners Mylan and Natco have cleared one hurdle to a potential U.S. launch of their ...

Bristol Myers Squibb's schizophrenia drug, which received FDA approval last week, took a long and winding road to get there. Three decades ago, Eli Lilly developed the drug's forerunner, xanomeline, ...